BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34041914)

  • 1. Analytical and Computational Methods for the Determination of Drug-Polymer Solubility and Miscibility.
    Thakore SD; Akhtar J; Jain R; Paudel A; Bansal AK
    Mol Pharm; 2021 Aug; 18(8):2835-2866. PubMed ID: 34041914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
    Meng F; Gala U; Chauhan H
    Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailoring supersaturation from amorphous solid dispersions.
    Li N; Taylor LS
    J Control Release; 2018 Jun; 279():114-125. PubMed ID: 29654798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Method of Constructing a Drug-Polymer Temperature-Composition Phase Diagram Using Hot-Melt Extrusion.
    Tian Y; Jones DS; Donnelly C; Brannigan T; Li S; Andrews GP
    Mol Pharm; 2018 Apr; 15(4):1379-1391. PubMed ID: 29205040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Qualitative and quantitative methods to determine miscibility in amorphous drug-polymer systems.
    Meng F; Dave V; Chauhan H
    Eur J Pharm Sci; 2015 Sep; 77():106-11. PubMed ID: 26006307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical Stability of Amorphous Solid Dispersions: a Physicochemical Perspective with Thermodynamic, Kinetic and Environmental Aspects.
    Lin X; Hu Y; Liu L; Su L; Li N; Yu J; Tang B; Yang Z
    Pharm Res; 2018 Apr; 35(6):125. PubMed ID: 29687226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of drug-polymer solubility from supersaturated spray-dried amorphous solid dispersions: A case study with Efavirenz and Soluplus®.
    Costa BLA; Sauceau M; Del Confetto S; Sescousse R; Ré MI
    Eur J Pharm Biopharm; 2019 Sep; 142():300-306. PubMed ID: 31247317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
    Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
    Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Development of Quasi-isothermal Calorimetry for the Measurement of Drug-Polymer Miscibility and Crystallization Kinetics: Olanzapine-Loaded PLGA Microparticles.
    Askin S; Zhao M; Gonçalves AD; Gaisford S; Craig DQM
    Mol Pharm; 2018 Aug; 15(8):3332-3342. PubMed ID: 29933697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fast and reliable empirical approach for estimating solubility of crystalline drugs in polymers for hot melt extrusion formulations.
    Kyeremateng SO; Pudlas M; Woehrle GH
    J Pharm Sci; 2014 Sep; 103(9):2847-2858. PubMed ID: 24634063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating crystallization tendency, miscibility, and molecular interactions of drug-polymer systems for the development of amorphous solid dispersions.
    Meng F; Paul SK; Borde S; Chauhan H
    Drug Dev Ind Pharm; 2021 Apr; 47(4):579-608. PubMed ID: 33651659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Flory-Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying.
    Tian Y; Caron V; Jones DS; Healy AM; Andrews GP
    J Pharm Pharmacol; 2014 Feb; 66(2):256-74. PubMed ID: 24192445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction and Construction of Drug-Polymer Binary System Thermodynamic Phase Diagram in Amorphous Solid Dispersions (ASDs).
    Hu Z; Xu P; Ashour EA; Repka MA
    AAPS PharmSciTech; 2022 Jun; 23(6):169. PubMed ID: 35715519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solvent influence on the phase behavior and glass transition of Amorphous Solid Dispersions.
    Dohrn S; Luebbert C; Lehmkemper K; Kyeremateng SO; Degenhardt M; Sadowski G
    Eur J Pharm Biopharm; 2021 Jan; 158():132-142. PubMed ID: 33212185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lacidipine Amorphous Solid Dispersion Based on Hot Melt Extrusion: Good Miscibility, Enhanced Dissolution, and Favorable Stability.
    Xi L; Song H; Wang Y; Gao H; Fu Q
    AAPS PharmSciTech; 2018 Oct; 19(7):3076-3084. PubMed ID: 30094722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular modeling as a predictive tool for the development of solid dispersions.
    Maniruzzaman M; Pang J; Morgan DJ; Douroumis D
    Mol Pharm; 2015 Apr; 12(4):1040-9. PubMed ID: 25734898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Thermal Imaging Method for Rapid Screening of Drug-Polymer Miscibility for Solid Dispersion Based Formulation Development.
    Alhijjaj M; Belton P; Fábián L; Wellner N; Reading M; Qi S
    Mol Pharm; 2018 Dec; 15(12):5625-5636. PubMed ID: 30372612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters.
    Marsac PJ; Li T; Taylor LS
    Pharm Res; 2009 Jan; 26(1):139-51. PubMed ID: 18779927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Drug-Polymer Miscibility on Enthalpy Relaxation of Irbesartan Amorphous Solid Dispersions.
    Dalsania S; Sharma J; Munjal B; Bansal AK
    Pharm Res; 2018 Jan; 35(2):29. PubMed ID: 29368174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.